You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞盛醫藥-B(06855.HK)共六項臨牀前進展亮相2022年美國癌症研究協會年會
格隆匯 04-14 07:03

格隆匯4月14日丨亞盛醫藥-B(06855.HK)發佈公吿,公司在剛剛舉行的2022年美國癌症研究協會(AACR)年會上公佈了六項最新臨牀前研究結果,包括公司細胞凋亡管線的兩個重要品種Bcl-2抑制劑lisaftoclax(APG-2575)、MDM2-p53 抑制劑alrizomadlin(APG-115),FAK抑制劑APG-2449,EED抑制劑APG-5918, KRAS抑制劑APG-1842五個在研品種。

根據披露,AACR年會是全球歷史最悠久、規模最大的腫瘤研究學術會議之一。會議關注高質量腫瘤研究及創新的各個方面,是全球腫瘤研究的焦點,將彙集腫瘤領域的最前沿的研究成果。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account